Phoenix Financial Ltd. Sells 2,222 Shares of McKesson Corporation $MCK

Posted by Linda Flegge on May 15th, 2026

Phoenix Financial Ltd. lessened its stake in shares of McKesson Corporation (NYSE:MCK – Free Report) by 19.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,098 shares of the company’s stock after selling 2,222 shares during the quarter. Phoenix Financial Ltd.’s holdings in McKesson were worth $7,468,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Thrivent Financial for Lutherans increased its holdings in McKesson by 2.1% during the 4th quarter. Thrivent Financial for Lutherans now owns 16,222 shares of the company’s stock valued at $13,365,000 after purchasing an additional 341 shares in the last quarter. Pinnacle Associates Ltd. increased its holdings in McKesson by 10.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 2,901 shares of the company’s stock valued at $2,379,000 after purchasing an additional 281 shares in the last quarter. Baader Bank Aktiengesellschaft increased its holdings in McKesson by 11.1% during the 4th quarter. Baader Bank Aktiengesellschaft now owns 629 shares of the company’s stock valued at $512,000 after purchasing an additional 63 shares in the last quarter. Allworth Financial LP increased its holdings in McKesson by 1.7% during the 4th quarter. Allworth Financial LP now owns 5,896 shares of the company’s stock valued at $4,836,000 after purchasing an additional 99 shares in the last quarter. Finally, Atria Investments Inc increased its holdings in McKesson by 4.2% during the 4th quarter. Atria Investments Inc now owns 12,571 shares of the company’s stock valued at $10,312,000 after purchasing an additional 510 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Stock Performance

NYSE MCK opened at $747.52 on Friday. The stock has a fifty day moving average of $859.18 and a 200-day moving average of $857.90. The stock has a market capitalization of $89.85 billion, a P/E ratio of 19.43, a price-to-earnings-growth ratio of 1.10 and a beta of 0.35. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. The company had revenue of $96.30 billion during the quarter, compared to analysts’ expectations of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period last year, the firm earned $10.12 EPS. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities research analysts forecast that McKesson Corporation will post 44.29 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 8.53%.

Insider Activity

In related news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,264 shares of company stock valued at $3,205,315. Company insiders own 0.08% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

Positive Sentiment: McKesson’s Q1 results showed non-GAAP EPS of $11.69, topping estimates, while revenue still rose 6% year over year to $96.3 billion. Management also said margin initiatives are continuing, which supports the long-term earnings story. MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continue
Positive Sentiment: Citigroup kept a Buy rating on McKesson and only slightly lowered its price target to $945 from $975, which still implies meaningful upside from recent trading levels. Benzinga
Positive Sentiment: McKesson Ventures helped lead a $26 million Series A round for BranchLab, a move that highlights the company’s continued investment in AI-enabled pharma commercialization and adjacent growth opportunities. BranchLab Raises $26M Series A Led by McKesson Ventures to Bring AI to Pharma Commercialization
Neutral Sentiment: McKesson is seeing elevated investor attention on Zacks, but the coverage appears to be mostly a reminder for investors to review the company’s fundamentals rather than a clear new catalyst. McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Neutral Sentiment: Another article highlighted analyst questions from McKesson’s Q1 earnings call, but it did not indicate a major new development by itself. 5 insightful analyst questions from McKesson’s Q1 earnings call
Negative Sentiment: McKesson’s revenue came in below analyst expectations in Q1, which may be a reason the stock has been trading lower despite solid earnings growth. MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continue

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Leerink Partners reaffirmed an “outperform” rating and set a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. Bank of America dropped their price target on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a report on Monday, April 6th. TD Cowen raised their price target on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a report on Thursday, February 5th. Finally, Barclays raised their price target on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $968.87.

View Our Latest Research Report on MCK

McKesson Company Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.